EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The immune checkpoint inhibitor avelumab increases aortic inflammation on [18F]FDG PET/CT: A retrospective cohort study

Anniek Strijdhorst iD, Reindert F Oostveen, Mark P A Schilder iD, Arthur J A T Braat iD, Youssef Chahid iD, Damini Dey, Nordin M J Hanssen, Hanneke W M van Laarhoven, Anne W van Schijndel, Tom T P Seijkens, Piotr J Slomka, Erik S G Stroes und 3 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0339671 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS One, 2025. Verfasst von Anniek Strijdhorst und 14 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Carcinoma, Merkel Cell, Aortitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with cancer treated with immune checkpoint inhibitors (ICIs) are at increased risk of cardiovascular events. Preclinical studies suggest that this may result from inflammation-induced destabilization of atherosclerotic plaques.

Objective

To evaluate changes in vessel wall inflammation assessed using [ 18 F]FDG positron emission tomography/computed tomography (PET/CT) after ICI initiation.

Methods

This was a single-center retrospective cohort study of patients with Merkel cell carcinoma who received at least one cycle of the programmed death ligand 1 (PD-L1) inhibitor avelumab and underwent [ 18 F]FDG PET/CT before initiation of treatment and after 3 months. The primary outcome was the change in the target-to-background ratio (TBR max ) in the descending aorta between baseline and first follow-up scan. Secondary outcomes included the change in TBR max in the carotid arteries, spleen, and bone marrow, and incidence of major adverse cardiovascular events.

Results

Fifty-three patients were included (66% male; median age 75 years). Most patients had established risk factors for cardiovascular disease (62%). The [ 18 F]FDG TBR max in the descending aorta increased from 1.52 (IQR, 1.39–1.70) at baseline to 1.64 (IQR, 1.41–1.97) after 3 months of treatment (change 7.8%. p = 0.022). No significant changes were observed in the carotid arteries, bone marrow, and spleen. Statin use was not associated with an attenuated change in TBR max. During a median follow-up of 2.3 (IQR, 1.5–4.2) years, one nonfatal ischemic stroke occurred.

Conclusion

Avelumab treatment was associated with an increase in [ 18 F]FDG uptake in the descending aorta after 3 months of treatment, which may be a potential marker of inflammation-driven accelerated atherosclerosis in patients receiving ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsCarcinoma, Merkel CellAortitisHumansMaleFemalePositron Emission Tomography Computed TomographyAgedRetrospective StudiesFluorodeoxyglucose F18Aged, 80 and overMiddle AgedInflammationAortaSkin Neoplasms

Substanzen

Antibodies, Monoclonal, HumanizedFluorodeoxyglucose F18Immune Checkpoint Inhibitorsavelumab

Autor:innen und Institutionen

  • Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, The Netherlands.
  • Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Medicine (Division of Artificial Intelligence), Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

ORCID-Profile: Anniek Strijdhorst, Mark P A Schilder, Arthur J A T Braat, Youssef Chahid

Zitieren

APA

Strijdhorst, A., Oostveen, R. F., Schilder, M. P. A., Braat, A. J. A. T., Chahid, Y., Dey, D., Hanssen, N. M. J., van Laarhoven, H. W. M., van Schijndel, A. W., Seijkens, T. T. P., Slomka, P. J., Stroes, E. S. G., Tesselaar, M., Verberne, H. J., & van Es, N. (2025). The immune checkpoint inhibitor avelumab increases aortic inflammation on [18F]FDG PET/CT: A retrospective cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0339671

Vancouver

Strijdhorst A, Oostveen RF, Schilder MPA, Braat AJAT, Chahid Y, Dey D, et al. The immune checkpoint inhibitor avelumab increases aortic inflammation on [18F]FDG PET/CT: A retrospective cohort study. PLOS One. 2025. doi:10.1371/journal.pone.0339671

BibTeX
@article{Strijdhorst2025,
  author = {Strijdhorst, Anniek and Oostveen, Reindert F and Schilder, Mark P A and Braat, Arthur J A T and Chahid, Youssef and Dey, Damini and Hanssen, Nordin M J and van Laarhoven, Hanneke W M and van Schijndel, Anne W and Seijkens, Tom T P and Slomka, Piotr J and Stroes, Erik S G and Tesselaar, Margot and Verberne, Hein J and van Es, Nick},
  title = {The immune checkpoint inhibitor avelumab increases aortic inflammation on [18F]FDG PET/CT: A retrospective cohort study},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0339671}
}
Kostenlos starten →